UnknownNot Applicable

A Prospective Study on Optimizing Treatment for ABPA

100 participantsStarted 2021-11-15

Plain-language summary

This study is being done to evaluate the efficacy of treatment using oral glucocorticoid, anti-fungal agent, anti-IgE mAb for patient with ABPA.

Who can participate

Age range18 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * 18\~75 years old, male or female * associated past medical history, including asthma, bronchiectasis, COPD ect. * elevated serum total IgE (\>100IU/mL) * elevated aspergillus specific IgE Exclusion Criteria: * According to the investigator, the patient has other factors that may affect the results of the study or lead to the termination of the study, such as alcohol abuse, drug abuse, other serious diseases (including mental illness). * Pregnancy or breastfeeding * Abnormality of liver or kidney function

What they're measuring

incidence of exacerbation: the exacerbation times indicated by symptoms and clinical index

Timeframe: Up to 6 months after last treatment dose

Trial details

NCT IDNCT05129033

SponsorShanghai Zhongshan Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2023-06-30

Contact for this trial

Meiling Jin, MD

+86 13701640522 mljin118@163.com

View on ClinicalTrials.gov More Allergic Bronchopulmonary Aspergillosis trials